Ticker Details
Ocular Therapeutix, Inc. Ocular Therapeutix Inc is a biopharmaceutical company. It is engaged in developing and commercializing therapies for diseases and conditions of the eye using its proprietary hydrogel platform technology.
IPO Date:	July 25, 2014
Sector:	Healthcare
Industry:	Biotech
Market Cap:	$2.02B
Activated in VL:	True

Average Daily Range
Avg Daily Range:	$0.28 | 3.20%
Avg Daily Range (30 D):	$0.37 | 4.20%
Avg Daily Range (90 D):	$0.38 | 3.70%

Institutional Daily Volume
Avg Daily Volume:	.94M
Avg Daily Volume (30 D):	4.32M
Avg Daily Volume (90 D):	4.84M

Trade Size
Avg Trade Size (Sh.):	128
Avg Trade Size (Sh.) (30 D):	120
Avg Trade Size (Sh.) (90 D):	119

Institutional Trades
Total Institutional Trades:	1,631
Avg Institutional Trade:	$2.02M
Avg Institutional Trade (30 D):	$2.23M
Avg Institutional Trade (90 D):	$2.19M
Avg Institutional Trade Volume:	.2M
Avg Institutional Trades (Per Day):	1

Market Closing Trades
Avg Closing Trade:	$2.37M
Avg Closing Trade (30 D):	$3.89M
Avg Closing Trade (90 D):	$4.4M
Avg Closing Volume:	241.16K

News

Feb 13, 2026 @ 10:00 PM Ocular Therapeutixâ„¢ to Announce Topline Data... Source: Na

Jan 26, 2026 @ 9:51 AM Corticosteroids Market Report 2026 - Global Indust... Source: Researchandmarkets.Com

Jan 15, 2026 @ 3:30 PM Ocular Therapeutix Shares Surge Following Reports ... Source: Dylan Berman

Dec 5, 2025 @ 12:00 PM Ocular Therapeutixâ„¢ Reports Inducement Grant... Source: Bill Slattery

Nov 7, 2025 @ 12:00 PM Ocular Therapeutixâ„¢ Reports Inducement Grant... Source: Bill Slattery

Financials
	TTM	Q4 2025	FY 2025
Basic EPS	$-1.42	$-.27	$-1.42
Diluted EPS	$-1.42	$-.27	$-1.42
Revenue	$51.95M	$13.25M	$51.95M
Gross Profit	$45.38M	$11.66M	$45.38M
Net Income / Loss	$-265.94M	$-64.65M	$-265.94M
Operating Income / Loss	$-270.02M	$-69.76M	$-270.02M
Cost of Revenue	$6.57M	$1.59M	$6.57M
Net Cash Flow	$344.96M	$392.29M	$344.96M
PE Ratio